ALIQOPA Drug Patent Profile
✉ Email this page to a colleague
When do Aliqopa patents expire, and when can generic versions of Aliqopa launch?
Aliqopa is a drug marketed by Bayer Healthcare and is included in one NDA. There are four patents protecting this drug.
This drug has one hundred and fifty-three patent family members in fifty countries.
The generic ingredient in ALIQOPA is copanlisib dihydrochloride. One supplier is listed for this compound. Additional details are available on the copanlisib dihydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Aliqopa
Aliqopa was eligible for patent challenges on September 14, 2021.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 29, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ALIQOPA
International Patents: | 153 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 15 |
Patent Applications: | 680 |
Drug Prices: | Drug price information for ALIQOPA |
What excipients (inactive ingredients) are in ALIQOPA? | ALIQOPA excipients list |
DailyMed Link: | ALIQOPA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for ALIQOPA
Generic Entry Date for ALIQOPA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ALIQOPA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NRG Oncology | Phase 2 |
City of Hope Medical Center | Phase 1/Phase 2 |
Dana-Farber Cancer Institute | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for ALIQOPA
US Patents and Regulatory Information for ALIQOPA
ALIQOPA is protected by four US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ALIQOPA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ALIQOPA
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Fused azole-pyrimidine derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
FDA Regulatory Exclusivity protecting ALIQOPA
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
Exclusivity Expiration: See Plans and Pricing
International Patents for ALIQOPA
When does loss-of-exclusivity occur for ALIQOPA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 09
Estimated Expiration: See Plans and Pricing
Argentina
Patent: 5718
Estimated Expiration: See Plans and Pricing
Australia
Patent: 12238891
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2013025549
Estimated Expiration: See Plans and Pricing
Canada
Patent: 32123
Estimated Expiration: See Plans and Pricing
Chile
Patent: 13002870
Estimated Expiration: See Plans and Pricing
China
Patent: 3649091
Estimated Expiration: See Plans and Pricing
Colombia
Patent: 81534
Estimated Expiration: See Plans and Pricing
Costa Rica
Patent: 130511
Estimated Expiration: See Plans and Pricing
Croatia
Patent: 0150138
Estimated Expiration: See Plans and Pricing
Cuba
Patent: 208
Estimated Expiration: See Plans and Pricing
Patent: 130133
Estimated Expiration: See Plans and Pricing
Cyprus
Patent: 16231
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 94508
Estimated Expiration: See Plans and Pricing
Dominican Republic
Patent: 013000223
Estimated Expiration: See Plans and Pricing
Ecuador
Patent: 13013006
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 3646
Estimated Expiration: See Plans and Pricing
Patent: 1391470
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 08525
Estimated Expiration: See Plans and Pricing
Patent: 94508
Estimated Expiration: See Plans and Pricing
Guatemala
Patent: 1300234
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 95907
Estimated Expiration: See Plans and Pricing
Israel
Patent: 8561
Estimated Expiration: See Plans and Pricing
Japan
Patent: 63834
Estimated Expiration: See Plans and Pricing
Patent: 26961
Estimated Expiration: See Plans and Pricing
Patent: 14510119
Estimated Expiration: See Plans and Pricing
Patent: 15164936
Estimated Expiration: See Plans and Pricing
Jordan
Patent: 58
Estimated Expiration: See Plans and Pricing
Malaysia
Patent: 9452
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 6057
Estimated Expiration: See Plans and Pricing
Patent: 13011583
Estimated Expiration: See Plans and Pricing
Montenegro
Patent: 021
Estimated Expiration: See Plans and Pricing
Morocco
Patent: 014
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 6198
Estimated Expiration: See Plans and Pricing
Peru
Patent: 141038
Estimated Expiration: See Plans and Pricing
Poland
Patent: 94508
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 94508
Estimated Expiration: See Plans and Pricing
San Marino
Patent: 01500037
Estimated Expiration: See Plans and Pricing
Serbia
Patent: 811
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 3595
Estimated Expiration: See Plans and Pricing
Slovenia
Patent: 94508
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1307105
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 1937501
Estimated Expiration: See Plans and Pricing
Patent: 140021637
Estimated Expiration: See Plans and Pricing
Spain
Patent: 29653
Estimated Expiration: See Plans and Pricing
Taiwan
Patent: 49954
Estimated Expiration: See Plans and Pricing
Patent: 92158
Estimated Expiration: See Plans and Pricing
Patent: 1249847
Estimated Expiration: See Plans and Pricing
Patent: 1637656
Estimated Expiration: See Plans and Pricing
Tunisia
Patent: 13000401
Estimated Expiration: See Plans and Pricing
Ukraine
Patent: 1604
Estimated Expiration: See Plans and Pricing
Uruguay
Patent: 985
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ALIQOPA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Croatia | P20150138 | See Plans and Pricing | |
Eurasian Patent Organization | 023646 | ЗАМЕЩЁННЫЕ СОЛИ 2,3-ДИГИДРОИМИДАЗО[1,2-C]ХИНАЗОЛИНА (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-c]QUINAZOLINE SALTS) | See Plans and Pricing |
Hong Kong | 1195907 | 取代的 -二氫咪唑並 喹唑啉鹽 (SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS 23-[12-C]) | See Plans and Pricing |
European Patent Office | 2508525 | Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitués (Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts) | See Plans and Pricing |
Jordan | 3147 | مشتقات 2،3 - داي هيدرو إميدازو}1،2-{c كينازولين بها استبدال مفيدة لعلاج اضطرابات فرط التكاثر الخلوي والامراض المتعلق بتولد الاوعية (Substituted 2,3-dihydroimidazo[ 1,2- c] quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders And Diseases Associated with Angiogenesis) | See Plans and Pricing |
China | 100384846 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |